| dbo:abstract |
JWH-133 (Dimethylbutyl-deoxy-Delta-8-THC) is a potent selective CB2 receptor agonist with a Ki of 3.4nM and selectivity of around 200x for CB2 over CB1 receptors. It was discovered by and named after, John W. Huffman. It's important to note that JWH-133 has been confused with other analogs of Delta-8-THC in professionally published peer-reviewed literature. Including being confused with Dimethylpentyl-Delta-8-THC as well as Dimethylbutyl-Delta-8-THC. Including confusing the chemical name with Dimethylbutyl-Delta-8-THC itself. Including confusing it with the Delta-9 isomer Including using the structural image of Dimethylbutyl-Delta-8-THC instead of Dimethylbutyl-deoxy-Delta-8-THC. It's important to note that 3-(1',1'-Dimethylbutyl)-1-deoxy-delta-8-THC is a selective CB2 agonist, binding 677nM at Cb1 and 3.4nM at CB2 while 3-(1',1'-Dimethylbutyl)-delta-8-THC itself binds 65nM at CB1. Structurally the only difference between JWH-133 and dimethylbutyl-D8-THC is that JWH-133 lacks the hydroxy group seen on dimethylbutyl-D8-THCs phenol structure (the C1 position of the A ring), turning this group into a phenyl (JWH-133) instead of phenol. It's generally accepted that removing the hydroxy group from the phenol structure of any classical cannabinoid benzoypran (such as THC) results in dramatically less CB1 activity and heightened CB2 activity. JWH-133, alongside WIN 55,212-2 and HU-210, is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's disease, in addition to preventing cognitive impairment and loss of neuronal markers. This anti-inflammatory action is induced through agonist action at the CB2 receptor, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids at this receptor completely abolish neurotoxicity related to microglia activation in rat models. It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in Madrid. (en) |
| dbo:casNumber |
259869-55-1 |
| dbo:chEBI |
146243 |
| dbo:chEMBL |
371214 |
| dbo:fdaUniiCode |
TDG8048RDA |
| dbo:pubchem |
6918505 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/JWH-133.png?width=300 |
| dbo:wikiPageID |
6286309 (xsd:integer) |
| dbo:wikiPageLength |
6768 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1117830684 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:John_W._Huffman dbc:Benzochromenes dbr:Amyloid_beta dbc:JWH_cannabinoids dbr:Madrid dbr:Microglia dbr:WIN_55,212-2 dbr:Dissociation_constant dbr:Alzheimer's_disease dbc:CB2_receptor_agonists dbr:HU-210 dbr:Cannabinoid_receptor_type_1 dbr:Cannabinoid_receptor_type_2 dbr:Neurotoxicity |
| dbp:c |
22 (xsd:integer) |
| dbp:casNumber |
259869 (xsd:integer) |
| dbp:chebi |
146243 (xsd:integer) |
| dbp:chembl |
371214 (xsd:integer) |
| dbp:chemspiderid |
5293702 (xsd:integer) |
| dbp:h |
32 (xsd:integer) |
| dbp:iupacName |
-3 (xsd:integer) |
| dbp:iupharLigand |
747 (xsd:integer) |
| dbp:o |
1 (xsd:integer) |
| dbp:pubchem |
6918505 (xsd:integer) |
| dbp:smiles |
O3c1ccCCCC (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
YSBFLLZNALVODA-RBUKOAKNSA-N (en) |
| dbp:unii |
TDG8048RDA (en) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
477496056 (xsd:integer) |
| dbp:width |
200 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Cannabinoidergics dbt:Cannabinoids dbt:Citation_needed dbt:Cite_journal dbt:Drugbox dbt:Refbegin dbt:Refend dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite |
| dcterms:subject |
dbc:Benzochromenes dbc:JWH_cannabinoids dbc:CB2_receptor_agonists |
| gold:hypernym |
dbr:Agonist |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatMolecularFormulas yago:Abstraction100002137 yago:Communication100033020 yago:Formula106816935 yago:Message106598915 yago:MolecularFormula106817173 dbo:Drug yago:Statement106722453 umbel-rc:DrugProduct |
| rdfs:comment |
JWH-133 (Dimethylbutyl-deoxy-Delta-8-THC) is a potent selective CB2 receptor agonist with a Ki of 3.4nM and selectivity of around 200x for CB2 over CB1 receptors. It was discovered by and named after, John W. Huffman. It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in Madrid. (en) |
| rdfs:label |
JWH-133 (en) |
| owl:sameAs |
freebase:JWH-133 wikidata:JWH-133 dbpedia-sh:JWH-133 dbpedia-sr:JWH-133 https://global.dbpedia.org/id/4nyJe |
| prov:wasDerivedFrom |
wikipedia-en:JWH-133?oldid=1117830684&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/JWH-133.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:JWH-133 |
| is dbo:wikiPageDisambiguates of |
dbr:JWH |
| is dbo:wikiPageRedirects of |
dbr:C22H32O |
| is dbo:wikiPageWikiLink of |
dbr:Capsazepine dbr:List_of_psychedelic_drugs dbr:JWH dbr:C22H32O dbr:WIN_55,212-2 dbr:Dronabinol dbr:List_of_JWH_cannabinoids dbr:HU-210 dbr:JWH-015 dbr:JWH-359 dbr:Tetrahydrocannabinol dbr:Cannabinoid dbr:Cannabinoid_receptor_type_2 |
| is foaf:primaryTopic of |
wikipedia-en:JWH-133 |
